硼替佐米治疗肺动脉高压的作用机制

doi:10.12092/j.issn.1009-2501.2019.08.018

中国临床药理学与治疗学 ›› 2019, Vol. 24 ›› Issue (8): 957-960.doi: 10.12092/j.issn.1009-2501.2019.08.018

• 综述与讲座 • 上一篇

硼替佐米治疗肺动脉高压的作用机制

王超，格根图雅，徐磊

内蒙古医科大学附属医院呼吸与危重症学科，呼和浩特 010059，内蒙古

收稿日期:2019-05-20 修回日期:2019-07-09 出版日期:2019-08-26 发布日期:2019-08-30
通讯作者: 徐磊，男，博士，副教授，研究方向: 肺动脉高压，肺癌。 E-mail：LXU81@126.com
作者简介:王超，男，硕士，主治医师，研究方向: 肺动脉高压。 E-mail: 420912490@qq.com
基金资助:
国家自然科学基金地区基金项目（81460011）；内蒙古卫计委课题（201702084）；内蒙古医科大学教改课题（YJG201824）

Mechanisms of bortezomib in the treatment of pulmonary hypertension

WANG Chao, GeGentuya, XU Lei

Department of Respiratory and Critical Care, the Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010059, Inner Mongolia, China

Received:2019-05-20 Revised:2019-07-09 Online:2019-08-26 Published:2019-08-30

摘要/Abstract

摘要：

硼替佐米可抑制多种细胞的增殖，目前用于多发性骨髓瘤、肿瘤的治疗中。肺动脉平滑肌细胞的增殖、重构是肺动脉高压的重要发病机制，在多种肺动脉高压大鼠模型中，硼替佐米可抑制肺血管的增厚、重构，但相关的研究仍较少，究其原因主要为调节机制不明确。本文就目前已发现的机制进行归纳，为硼替佐米在肺动脉高压中的应用提供参考。

关键词: 硼替佐米, 肺动脉高压

Abstract:

Bortezomib (BTZ) can inhibit the proliferation of many kinds of cell. Studies have shown promising evidence of BTZ in the treatment of multiple myeloma and tumor. To date, researchers have believed the proliferation and migration of pulmonary artery smooth muscle cells (PASMC) play as the two major causes that induce the excessive thickening and remodeling of the distal pulmonary arteries (PA), which drives the disease pathogenesis of pulmonary hypertension (PH). Lately, a number of recent studies have indicated that BTZ can effectively suppress the PH development in multiple commonly used PH rat models via inhibiting the distal PA remodeling and PASMC proliferation. However, neither the underlying molecular mechanism nor the related clinical relevance are fully understood and remain future dissection. Therefore, in this review, we briefly summarize the recent published literature, which provide mechanistic evidence to guide the utilization of BTZ as a potential novel treatment option in PH and other pulmonary vascular diseases.

Key words: bortezomib, pulmonary hypertension

中图分类号:

R543.2

王超，格根图雅，徐磊. 硼替佐米治疗肺动脉高压的作用机制[J]. 中国临床药理学与治疗学, 2019, 24(8): 957-960.

WANG Chao, GeGentuya, XU Lei. Mechanisms of bortezomib in the treatment of pulmonary hypertension[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 957-960.

参考文献

［1］de Jesus Perez VA. Molecular pathogenesis and current pathology of pulmonary hypertension［J］. Heart Fail Rev, 2016,21(3):239-257.
［2］魏子寒,李栋博,元峥,等.沙库巴曲缬沙坦治疗左心疾病相关性肺动脉高压的临床研究［J］.中国临床药理学与治疗学,2019,24(1):57-62.
［3］Oka M, Homma N, Taraseviciene-Stewart L, et al. Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats［J］. Circ Res, 2007,100(6):923-929.
［4］Wade BE, Zhao J, Ma J, et al. Hypoxia-induced alterations in the lung ubiquitin proteasome system during pulmonary hypertension pathogenesis［J］. Pulm Circ, 2018, 8(3):1-13
［5］Kaufman JL, Nooka A, Vrana M, et al. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study［J］.Cancer, 2010,116(13):3143-3151.
［6］Hussein MA. Nontraditional cytotoxic therapies for relapsed/refractory multiple myeloma［J］. Oncologist, 2002, 7 (Suppl 1): 20-29.
［7］Ri M. Role of novel proteasome inhibitors in the treatment of relapsed/refractory multiple myeloma［J］. Rinsho Ketsueki, 2018, 59(10): 2162-2168.
［8］Rogers N, Paine S, Bedford L, et al. Review: the ubiquitin-proteasome system: contributions to cell death or survival in neurodegeneration［J］. Neuropathol Appl Neurobiol, 2010,36(2):113-124.
［9］Moore BS, Eustáquio AS, McGlinchey RP. Advances in and applications of proteasome inhibitors［J］. Curr Opin Chem Biol, 2008,12(4):434-440.
［10］Harrison BC, Bell ML, Allen DL, et al. Skeletal muscle adaptations in response to voluntary wheel running in myosin heavy chain null mice［J］. J Appl Physiol，2002,92(1):313-322.
［11］Kim SY, Lee JH, Huh JW, et al. Bortezomib alleviates experimental pulmonary arterial hypertension［J］. Am J Respir Cell Mol Biol, 2012,47(5):698-708.
［12］Wang Z, Yang K, Zheng Q, et al. Divergent Changes of p53 in pulmonary arterial endothelial and smooth muscle cells involved in the development of pulmonary hypertension［J］. Am J Physiol Lung Cell Mol Physiol, 2018, 316(1):L216-L228.
［13］Xie X, Wang G, Zhang D, et al. Activation of peroxisome proliferator-activated receptor γ ameliorates monocrotaline-induced pulmonary arterial hypertension in rats［J］.Biomed Rep,2015,3(4):537-542.
［14］Wang Y, Lu W, Yang K, et al. Peroxisome proliferator-activated receptor γ inhibits pulmonary hypertension targeting store-operated calcium entry［J］.J Mol Med (Berl),2015,93(3):327-342.
［15］Lee YR, Chen M, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor: new modes and prospects［J］. Nat Rev Mol Cell Biol, 2018,19(9):547-562.
［16］Kuhr FK, Smith KA, Song MY, et al. New mechanisms of pulmonary arterial hypertension: role of Ca2+ signaling［J］. Am J Physiol Heart Circ Physiol, 2012, 302(8): H1546-1562.
［17］Wang J, Weigand L, Lu W, et al. Hypoxia inducible factor 1 mediates hypoxia-induced TRPC expression and elevated intracellular Ca2+ in pulmonary arterial smooth muscle cells［J］. Circ Res, 2006,98(12):1528-1537.
［18］徐磊, 田国英, 王立红, 等. 硼替佐米对低氧诱导的肺动脉平滑肌细胞Orai-1蛋白表达的影响［J］.中华结核和呼吸杂志,2017,(2):118-122.
［19］Ibrahim YF, Wong CM, Pavlickova L, et al. Mechanism of the susceptibility of remodeled pulmonary vessels to drug-induced cell killing［J］. J Am Heart Assoc, 2014,3(1):e000520.
［20］Wong CM, Cheema AK, Zhang L, et al. Protein carbonylation as a novel mechanism in redox signaling［J］. Circ Res, 2008,102(3):310-318.
［21］Lee SJ, Smith A, Guo L, et al. Autophagic protein LC3B confers resistance against hypoxia-induced pulmonary hypertension［J］. Am J Respir Crit Care Med, 2011,183(5):649-658.
［22］Jiang J, Cyr D, Babbitt RW, et al. Chaperone-dependent regulation of endothelial nitric-oxide synthase intracellular trafficking by the co-chaperone/ubiquitin ligase CHIP［J］. J Biol Chem, 2003,278(49):49332-49341.
［23］Michel T, Vanhoutte PM. Cellular signaling and NO production［J］. Pflugers Arch, 2010,459(6):807-816.
［24］Inoue I, Goto S, Matsunaga T, et al. The ligands/activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma increase Cu2+,Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells［J］. Metabolism, 2001,50(1):3-11.
［25］Kaplan GS, Torcun CC, Grune T, et al. Proteasome inhibitors in cancer therapy: Treatment regimen and peripheral neuropathy as a side effect［J］. Free Radic Biol Med, 2017,103:1-13.
［26］Jaggi AS, Singh N. Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy［J］. Toxicol, 2012,291(1-3):1-9.
［27］Karademir B, Sari G, Jannuzzi AT, et al. Proteomic approach for understanding milder neurotoxicity of Carfilzomib against Bortezomib［J］. Sci Rep, 2018,8(1):16318.
［28］Wang X, Ibrahim YF, Das D, et al. Carfilzomib reverses pulmonary arterial hypertension［J］. Cardiovasc Res, 2016,110(2):188-199.

[1]	沈畅, 艾可龙, 胡长平. 低氧诱导因子1信号通路调控低氧性肺动脉高压研究进展[J]. 中国临床药理学与治疗学, 2023, 28(1): 114-120.
[2]	孟时, 王中群. 人类免疫缺陷病毒相关性肺动脉高压研究进展[J]. 中国临床药理学与治疗学, 2022, 27(12): 1431-1440.
[3]	王睿, 潘进进, 李华, 袁予辉. 褪黑素调节肺动脉高压的作用与机制研究进展[J]. 中国临床药理学与治疗学, 2021, 26(4): 444-448.
[4]	胡晓燕, 徐秋萍. 左西孟旦在心脏外科术后重症患者的应用研究[J]. 中国临床药理学与治疗学, 2020, 25(9): 1027-1032.
[5]	徐静，金晓洁. 法舒地尔联合西地那非治疗肺动脉高压大鼠疗效观察[J]. 中国临床药理学与治疗学, 2017, 22(3): 281-286.
[6]	黄友明, 王安才, 查日田. 舒利迭联合茶碱对慢性阻塞性肺疾病稳定期患者肺动脉压及右心功能的观察[J]. 中国临床药理学与治疗学, 2014, 19(8): 920-925.
[7]	陈辉, 瞿丽, 黄永刚. 硼替佐米对胃癌细胞的抗肿瘤作用及其机制[J]. 中国临床药理学与治疗学, 2013, 18(6): 606-609.
[8]	武彩霞, 杜冠华. 肺血管内皮损伤与肺动脉高压[J]. 中国临床药理学与治疗学, 2012, 17(4): 463-471.
[9]	唐兰兰, 王淑君, 黎关龙, 王园园, 周俊辉, 赵珊, 刘亚坤, 王万铁. 三七皂苷单体R₁对低氧高二氧化碳肺动脉平滑肌细胞ERK1/2表达的影响[J]. 中国临床药理学与治疗学, 2011, 16(11): 1216-1221.
[10]	肖雄, 侯颖, 李小强. 5-羟色胺受体拮抗剂在肺动脉高压防治中的应用与展望[J]. 中国临床药理学与治疗学, 2011, 16(1): 111-115.
[11]	王新, 杨玉雯, 王安才, 孔祥权. 缬沙坦干预对缺氧性肺动脉高压大鼠大电导钙激活钾通道的影响[J]. 中国临床药理学与治疗学, 2009, 14(9): 1032-1035.
[12]	吴军, 王良兴, 应斌宇, 施孟如. 葛根素干预肺动脉高压大鼠时钙网蛋白前体变化的研究[J]. 中国临床药理学与治疗学, 2009, 14(1): 14-19.
[13]	周永列, 吕亚萍, 许武林, 胡惟孝. 连续荧光监测法测定蛋白酶体活性及其在筛选蛋白酶体抑制剂中的应用[J]. 中国临床药理学与治疗学, 2008, 13(10): 1127-1133.
[14]	李娜, 王秋娟, 戴德哉, 贺海波, 冯瑜, 戴茵. 内皮素受体拮抗剂CPU0213 对博莱霉素及油酸的小鼠肺损伤及纤维化的改善作用[J]. 中国临床药理学与治疗学, 2007, 12(9): 998-1003.
[15]	莫碧文, 曾锦荣, 李国坚, 黄文新, 于方, 王绩英, 王昌明. 氯离子通道阻断剂对大鼠低氧性肺动脉高压的影响[J]. 中国临床药理学与治疗学, 2006, 11(6): 677-680.

硼替佐米治疗肺动脉高压的作用机制

Mechanisms of bortezomib in the treatment of pulmonary hypertension

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价